Afleveringen
-
In this episode of NETCast, Dr. Jason Starr engages with patient advocacy leaders in the NET community to review highlights and insights from the 2024 NANETS Annual Symposium. Lisa Yen, Jessica Thomas, and Josh Mailman discuss the evolving role of patients in their care, the need for more therapies for neuroendocrine carcinoma, and the significance of building trust between patients and healthcare providers. The panelists share their experiences and strategies for empowering patients and bridging gaps in clinical trials and education.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
In this episode, Dr. Aman Chauhan joins Dr. Renuka Iyer to discuss the critical updates in neuroendocrine tumors, focusing on the AJCC staging system and its implications for clinical practice. The conversation covers the evolution of staging systems, the role of biomarkers like chromogranin A, the importance of endoscopists in management, and the outcomes for appendiceal neuroendocrine tumors. The episode emphasizes the need for updated guidelines to improve patient care and outcomes in the field of oncology.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
DLL3 approval in eSCLC and how it can be used in extrapulmonary PDNEC/small cell. Dr. Phan speaks with Dr. Jain about treatment options for neuroendocrine carcinoma.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
NET Regional Education Conference Jointly Provided by The University of Minnesota and The Mayo Clinic. Dr. Lou and Dr. Halfdanarson spoke with Dr. Phan and Dr. Chandrasekharan about Systemic Therapy for NETs Beyond SSAs (Including Sequencing) and Well-differentiated G3 NETs.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Join us for Episode 24 of NETCast. Mayo Clinical Gastrointestinal Oncologist Dr. Jason Starr interviews Lisa Yen from LACNETS and Stephanie Alband from INCA and The PheoPara Alliance, patient advocacy groups that partner with NANETS. Join us as we discuss ways we are Bridging the Gap for patient advocacy.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Join us for Episode 23 of NETCast. Ohio State University Medical Oncology Specialist Dr. Vineeth Sukrithan interviews Dr. Simron Singh professor of medicine at the University of Toronto and co-founder of the Susan Leslie Clinic for Neuroendocrine Tumors. He is also a medical oncologist and affiliate scientist in the Odette Cancer Research Program at Sunnybrook Research Institute. Join us as we review the NETTER-1 study and then discuss the NETTER-2 study.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Join us for Episode 22 of NETCast. Mayo Clinical Gastrointestinal Oncologist Dr. Jason Starr interviews Hematologist & Oncologist Dr. Bassam Sonbol about bone marrow toxicity associated with PRRT.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Dr. Heloisa Soares is a medical oncologist and Associate Professor at the Huntsman Cancer Institute (HCI) at Universityof Utah. Neuroendocrine tumors and gastrointestinal (GI) cancers are the major focus of her research and clinical activities.
Dr. Soares serves as the Medical Director for the Clinical Trials Office as well as the co-physician leader in the GI Clinical Trials Research Group at HCI. She is a past member of NANETS’ Board of Directors and currently serves as Chair of NANETS’ NETPact Committee.
Dr. Soares is a passionate patient advocate and a Healing NET Foundation Board Member. Along with many patient-centered activities, she volunteers at the ASCO Advocacy Summit on Capital Hill. Dr. Soares is one of our distinguished Guest Discussants on today’s podcast.
Dr. Timothy Hobday is a medical oncologist at the Mayo Clinic Comprehensive Cancer Center. He is a member of the Breast Clinic and Nuclear Medicine Therapy specialty groups. His focus is breast cancer, neuroendocrine tumors, and pancreatic neuroendocrine tumors.
His clinical research is focused on novel targeted therapies for neuroendocrine tumors and breast cancer, contributing significantly to advancements in these fields. His educational background includes a Hematology/Oncology Fellowship and an Internal Medicine Residency, both completed at the Mayo Clinic College of Medicine.
Dr. Hobday is a longtime member of NANETS and a frequent speaker at our conferences and educational programs.
Dr. Virginia Corbett is a medical oncologist at Mount Sinai Medical Center, NYC, where she has been in practice for nine years. Her focus is on liver cancers and neuroendocrine tumors.
She received her MD from Michigan State University- College of Human Medicine and her residency in internal medicine at NY Presbyterian Hospital – Weill Cornell. She completed her residency at Mount Sinai.
Dr. Corbett is a new member of NANETS and currently serves on its Early Career Development Committee. She is today’s Guest Moderator. We welcome her to NETCast!
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Join us for Episode 20 of NETCast. Today we are excited to bring a live taping from the NET Regional Education Conference, at U Miami Health and jointly provided by Sylvester Comprehensive Cancer Center and NANETS.
Our guest moderator is Aman Chuahan, MD, is a medical oncologist at University of Miami, Leader of the Neuroendocrine Cancer Program and co-leader of the Diagnostic Drug Development program at Sylvester Comprehensive Cancer Center, and Co-Chair of NANETS Communications Committee.
He is joined by guest participants who attended ENETS and will share some of their impressions:
Jaydira del Rivero, MD, Asst. Research Physician and Director Rare Tumor Clinic, Center for Cancer Research, National Cancer Institute, and member of NANETS’ Executive Board of Directors;
Thorvardur Halfdanarson, MD, Medical Oncology, Associate Professor, Mayo Clinic, President, NANETS Board of Directors; and
Simron Singh, MD, MPH, FRCPC, Medical Oncologist, Odette Cancer Center at Sunnybrook Health Sciences Center, Adjunct Professor, University of Toronto, and Secretary of NANETS’ Board of Directors.
Today’s topic is sure to engage many of you who were unable to attend the ENETS conference, and many of you who will want to tune in to hear about things you may have missed at the conference!
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
In this episode, Dr. Jason Starr. medical oncologist with Mayo Clinic, and Chair of NANETS Communications Committee, talks with NANETS Communications Director Maureen Werther about their goals and projects planned for 2024. Collaboration is the key focal point in '24. Tune in and learn about upcoming webinars, podcasts, programs and events that will be hosted jointly with our partners in the neuroendocrine field.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Dr. Simron Singh is a medical oncologist, affiliate scientist in the Odette Cancer Research Program at Sunnybrook Research Institute, and an assistant professor at the University of Toronto. Dr. Singh is a longtime member of NANETS and the current Treasurer of its Board of Directors.
Dr. Alexandria T. Phan is a Professor of Internal Medicine and Medical Oncology at Froedtert & Medical College of Wisconsin, with a special focus on neuroendocrine tumors and malignancies of the GI tract. Dr. Phan is a member of NANETS' Communications and the moderator of this discussion. The doctors will discuss highlights from the recent ASCO meeting, with a special focus on the results of the phase 3 randomized NETTER-2 study. This is the first randomized study to demonstrate efficacy of RLT as 1L treatment in any malignancy and will change clinical practice.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
NET medical professionals gathered in Detroit in November 2023 to discuss highlights from NANETS' 2023 Multidisciplinary NET Medical Symposium held the previous month in Montreal. Internationally renowned cancer researcher and medical oncologist, Philip A. Philip, MD, PhD, Wayne State University, moderated a discussion with fellow NET medical professionals: Jonathan Strosberg, MD, who leads Moffitt’s Neuroendocrine Tumor Division and Department of Gastrointestinal Oncology Research Program; and Amr Mohamed, MD, Director of the Neuroendocrine Tumor Program at University Hospitals Seidman Cancer Center. Topics included surgical treatment for G3 NENs, ongoing and recently completed clinical trials that have the potential to change the current landscape for NENs, and more cutting-edge topics.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Here’s the latest episode of NETCast, recorded live at #NANETS 2023 Symposium in Montreal. Guest moderator, Dr. David Zhen, GI, Medical Oncology, Fred Hutchinson Cancer Center, is joined by Dr. Jennifer Eads, MD, Medical Oncology, Penn Medicine, Dr. Jennifer Chan, Medical Oncology, Dana-Farber Cancer Institute, and Josh Mailman,fierce patient advocate and President of the NET advocacy group NorCal CarciNET for an eye-opening conversation about ongoing/upcoming clinical trials, challenges facing both investigators and patients for NET clinical trials, and most importantly, implications for patients.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Dr. Gaby Gabriel, Associate Professor of Radiology and Surgery at U. of Kentucky, and member, NANETS Communications Committee, is our guest moderator for this commonly encountered management decision in NETs. He is joined by a distinguished panel of guest discussants: Dr. Callisia Clarke, Surgical Oncology, Medical College of Wisconsin; Dr. Nicholas Fidelman, Interventional Radiology, UCSF; and Dr. Michael Soulen, Interventional Radiology, Penn Medicine.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
In this NETCast episode, guest Moderator, Virginia Corbett, MD, Oncology, Mt Sinai Hospital, is joined by NANETS President, Dr. Thorvardur Halfdanarson, Medical Oncology, Mayo Clinic, and Dr. Nitya Raj, Medical Oncology, Memorial Sloan Kettering,
for a lively, open forum discussion on the always interesting and sometimes controversial topic of biomarkers in NETs.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Tune in to NETCast to hear this recent discussion of an emerging topic in NET treatment, particularly PRRT.Participants include: Moderator Jaydira del Rivero, MD, Endocrine Oncology, National Cancer Institute, National Institutes of Health, and member of NANETS Board of Directors; Discussants – Aman Chauhan, MD, MedicalOncology, U. of Miami, Sylvester Cancer Center; and Hagen Kennecke, MD, M.D., MHA, FRCP, Medical Oncology and Medical Director of Gastrointestinal (GI) Oncology, Providence Cancer Institute.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
In this episode of NETCast, recorded live on the final day of #NANETS2023, participants from the conference review the highlights of this year’s symposium, held in the beautiful city of Montreal, Quebec. Most importantly, find out who tried the poutine! The moderator of this episode is Jason Starr, DO, Medical Oncology, Mayo Clinic and Chair of NANETS Communications Committee. He is joined by the newly installed NANETS President, Thorvardur Halfdanarson, MD, Medical Oncology, Mayo Clinic; and Symposium Program Chairs, Bart Rose, MD, MAS, FACS, Surgical Oncology, U. of Alabama Birmingham, and Po Hien Ear, PhD, Basic/Translational Science, U. of Iowa.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
In this episode of NETCast, " When Surgery is Indicated in NETs from G1- G3," we hear from a distinguished panel of leading NET medical professionals, including Dr. Julie Hallet, Odette Cancer Centre at the Sunnybrook Health Sciences Centre, Dr. Callisia Clarke, Medical College of Wisconsin, Dr. Alexandra Gangi, Cedars Sinai Samuel Oschin Comprehensive Cancer Institute, and Dr. Aman Chauhan, University of Miami.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
A conversation with Anees Chagpar, MD, MSc, MPH, MA, MBA, FRCS(C) FACS, Professor, Dept of Surgery, Yale University School of Medicine about her upcoming Presentation at the NANETS 2nd Annual Women in NETS Luncheon, Fri, Oct. 6, 2023 in Montreal: "Negotiation 101: How to Grow the Pie and Get Your Fair Share."
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
In this episode of NETCast, which was taped live during NANETS' Cleveland NET Regional Educational Conference, leading NET medical experts held a discussion of Hormonal Management of NETs: Syndromes and Symptom Control, moderated by Amr Mohamed, MD, UH Seidman Cancer Center, University Hospital, and guests Lauren Fishbein, MD, PhD, University of Colorado, and Thorvardur Halfdanarson, MD, Mayo Clinic. Dr. Mohamed, who also served as Course Director for the NET Regional, is a medical oncologist at UH Hospitals Seidman Cancer Center, focusing on development of targeted therapies for patients with GI cancers, especially neuroendocrine tumors and colorectal cancer. Dr. Fishbein's research interests are to understand what causes neuroendocrine tumors to form (pheochromocytomas, paragangliomas, gastrointestinal and pancreatic neuroendocrine tumors). She is particularly interested in studying the inherited and tumor specific genetic changes that lead to tumor formation. Dr. Halfdanarson specializes in GI oncology. He is the program director for the Hematology/Oncology Fellowship Program at Mayo Clinic and is the current VP of the North American Neuroendocrine Tumor Society.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
- Laat meer zien
